Ex-HHS Sec­re­tary Tom­my Thomp­son adds an­oth­er biotech to his re­sume; Medi­gene OK'd for first TCR clin­i­cal tri­al

→ For­mer HHS Sec­re­tary Tom­my Thomp­son is ex­pand­ing his biotech re­sume. Thomp­son has signed as a board mem­ber at New York-based Tyme Tech­nolo­gies, which is work­ing on a pipeline of can­cer ther­a­pies. Thomp­son is al­so chair­man of Ther­a­peu­tic­sMD, which re­cent­ly won a re­ver­sal of the FDA’s de­ci­sion to re­ject its lead ther­a­py and per­mit a full re­view of its mar­ket­ing ap­pli­ca­tion.

→ Medi­gene AG has gained a reg­u­la­to­ry green light to be­gin the first Phase I/II study of its TCR-mod­i­fied T cell ther­a­py MDG1011. “With our spe­cif­ic study de­sign, we are able to eval­u­ate our T cell ther­a­py si­mul­ta­ne­ous­ly in var­i­ous dis­eases and to gen­er­ate da­ta in three hema­to­log­i­cal in­di­ca­tions in par­al­lel,” said Kai Pinck­er­nell, the CMO at Medi­gene.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER